低プロトロンビン血症治療のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Hypoprothrombinemia Treatment Market Insights, Forecast to 2028

• レポートコード：QY2207E09235 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の低プロトロンビン血症治療の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に低プロトロンビン血症治療の世界市場のxxx％を占める「タイプI欠乏症治療」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の低プロトロンビン血症治療の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの低プロトロンビン血症治療市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの低プロトロンビン血症治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 低プロトロンビン血症治療のグローバル主要メーカーには、Roche、Abbott、Takeda Pharmaceutical Company、CSL Limited、Bayer、Pfizer、Novo Nordisk、Grifols、Biogen、BioMarin、BioSyent、Glenmark Pharmaceuticals、Amarna Therapeutics、Alnylam Pharmaceuticals、Teva Pharmaceutical Industries、Mylan、Integra LifeSciences、Enzo Biochem、Emcure、Amgen、Emergent、Baxter、Medtronic、Dr. Reddy’s Laboratories、Amneal Pharmaceuticals、Octapharma、Epitomepharm、Viramalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 低プロトロンビン血症治療市場は、種類と用途によって区分されます。世界の低プロトロンビン血症治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 タイプI欠乏症治療、タイプII欠乏症治療 【用途別セグメント】 病院、ホームケア、スペシャリストクリニック 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 低プロトロンビン血症治療製品概要 - 種類別市場（タイプI欠乏症治療、タイプII欠乏症治療） - 用途別市場（病院、ホームケア、スペシャリストクリニック） - 調査の目的 ・エグゼクティブサマリー - 世界の低プロトロンビン血症治療販売量予測2017-2028 - 世界の低プロトロンビン血症治療売上予測2017-2028 - 低プロトロンビン血症治療の地域別販売量 - 低プロトロンビン血症治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別低プロトロンビン血症治療販売量 - 主要メーカー別低プロトロンビン血症治療売上 - 主要メーカー別低プロトロンビン血症治療価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（タイプI欠乏症治療、タイプII欠乏症治療） - 低プロトロンビン血症治療の種類別販売量 - 低プロトロンビン血症治療の種類別売上 - 低プロトロンビン血症治療の種類別価格 ・用途別市場規模（病院、ホームケア、スペシャリストクリニック） - 低プロトロンビン血症治療の用途別販売量 - 低プロトロンビン血症治療の用途別売上 - 低プロトロンビン血症治療の用途別価格 ・北米市場 - 北米の低プロトロンビン血症治療市場規模（種類別、用途別） - 主要国別の低プロトロンビン血症治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの低プロトロンビン血症治療市場規模（種類別、用途別） - 主要国別の低プロトロンビン血症治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の低プロトロンビン血症治療市場規模（種類別、用途別） - 主要国別の低プロトロンビン血症治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の低プロトロンビン血症治療市場規模（種類別、用途別） - 主要国別の低プロトロンビン血症治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの低プロトロンビン血症治療市場規模（種類別、用途別） - 主要国別の低プロトロンビン血症治療市場規模（トルコ、サウジアラビア） ・企業情報 Roche、Abbott、Takeda Pharmaceutical Company、CSL Limited、Bayer、Pfizer、Novo Nordisk、Grifols、Biogen、BioMarin、BioSyent、Glenmark Pharmaceuticals、Amarna Therapeutics、Alnylam Pharmaceuticals、Teva Pharmaceutical Industries、Mylan、Integra LifeSciences、Enzo Biochem、Emcure、Amgen、Emergent、Baxter、Medtronic、Dr. Reddy’s Laboratories、Amneal Pharmaceuticals、Octapharma、Epitomepharm、Viramal ・産業チェーン及び販売チャネル分析 - 低プロトロンビン血症治療の産業チェーン分析 - 低プロトロンビン血症治療の原材料 - 低プロトロンビン血症治療の生産プロセス - 低プロトロンビン血症治療の販売及びマーケティング - 低プロトロンビン血症治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 低プロトロンビン血症治療の産業動向 - 低プロトロンビン血症治療のマーケットドライバー - 低プロトロンビン血症治療の課題 - 低プロトロンビン血症治療の阻害要因 ・主な調査結果

Hypoprothrombinemia is basically a rare bleeding disorder, which may be acquired or inherited. Under this disorder, a deficiency of the blood-clotting substance prothrombin (Factor II) is produced in the liver. The deficiency further results in a dysfunctional of blood clotting mechanism, leading to an increased physiological risk for spontaneous bleeding.
Market Analysis and Insights: Global Hypoprothrombinemia Treatment Market
The global Hypoprothrombinemia Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Type I Deficiency Treatment accounting for % of the Hypoprothrombinemia Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Hypoprothrombinemia Treatment market size is valued at US$ million in 2021, while the North America and Europe Hypoprothrombinemia Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Hypoprothrombinemia Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hypoprothrombinemia Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hypoprothrombinemia Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hypoprothrombinemia Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hypoprothrombinemia Treatment market.
Global Hypoprothrombinemia Treatment Scope and Market Size
Hypoprothrombinemia Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Hypoprothrombinemia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Type I Deficiency Treatment
Type II Deficiency Treatment
Segment by Application
Hospital
Home Care
Specialist Clinic
By Company
Roche
Abbott
Takeda Pharmaceutical Company
CSL Limited
Bayer
Pfizer
Novo Nordisk
Grifols
Biogen
BioMarin
BioSyent
Glenmark Pharmaceuticals
Amarna Therapeutics
Alnylam Pharmaceuticals
Teva Pharmaceutical Industries
Mylan
Integra LifeSciences
Enzo Biochem
Emcure
Amgen
Emergent
Baxter
Medtronic
Dr. Reddy’s Laboratories
Amneal Pharmaceuticals
Octapharma
Epitomepharm
Viramal
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

---

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hypoprothrombinemia Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Type I Deficiency Treatment
1.2.3 Type II Deficiency Treatment
1.3 Market by Application
1.3.1 Global Hypoprothrombinemia Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Home Care
1.3.4 Specialist Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hypoprothrombinemia Treatment Market Perspective (2017-2028)
2.2 Hypoprothrombinemia Treatment Growth Trends by Region
2.2.1 Hypoprothrombinemia Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Hypoprothrombinemia Treatment Historic Market Size by Region (2017-2022)
2.2.3 Hypoprothrombinemia Treatment Forecasted Market Size by Region (2023-2028)
2.3 Hypoprothrombinemia Treatment Market Dynamics
2.3.1 Hypoprothrombinemia Treatment Industry Trends
2.3.2 Hypoprothrombinemia Treatment Market Drivers
2.3.3 Hypoprothrombinemia Treatment Market Challenges
2.3.4 Hypoprothrombinemia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hypoprothrombinemia Treatment Players by Revenue
3.1.1 Global Top Hypoprothrombinemia Treatment Players by Revenue (2017-2022)
3.1.2 Global Hypoprothrombinemia Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Hypoprothrombinemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hypoprothrombinemia Treatment Revenue
3.4 Global Hypoprothrombinemia Treatment Market Concentration Ratio
3.4.1 Global Hypoprothrombinemia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hypoprothrombinemia Treatment Revenue in 2021
3.5 Hypoprothrombinemia Treatment Key Players Head office and Area Served
3.6 Key Players Hypoprothrombinemia Treatment Product Solution and Service
3.7 Date of Enter into Hypoprothrombinemia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hypoprothrombinemia Treatment Breakdown Data by Type
4.1 Global Hypoprothrombinemia Treatment Historic Market Size by Type (2017-2022)
4.2 Global Hypoprothrombinemia Treatment Forecasted Market Size by Type (2023-2028)
5 Hypoprothrombinemia Treatment Breakdown Data by Application
5.1 Global Hypoprothrombinemia Treatment Historic Market Size by Application (2017-2022)
5.2 Global Hypoprothrombinemia Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Hypoprothrombinemia Treatment Market Size (2017-2028)
6.2 North America Hypoprothrombinemia Treatment Market Size by Type
6.2.1 North America Hypoprothrombinemia Treatment Market Size by Type (2017-2022)
6.2.2 North America Hypoprothrombinemia Treatment Market Size by Type (2023-2028)
6.2.3 North America Hypoprothrombinemia Treatment Market Share by Type (2017-2028)
6.3 North America Hypoprothrombinemia Treatment Market Size by Application
6.3.1 North America Hypoprothrombinemia Treatment Market Size by Application (2017-2022)
6.3.2 North America Hypoprothrombinemia Treatment Market Size by Application (2023-2028)
6.3.3 North America Hypoprothrombinemia Treatment Market Share by Application (2017-2028)
6.4 North America Hypoprothrombinemia Treatment Market Size by Country
6.4.1 North America Hypoprothrombinemia Treatment Market Size by Country (2017-2022)
6.4.2 North America Hypoprothrombinemia Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Hypoprothrombinemia Treatment Market Size (2017-2028)
7.2 Europe Hypoprothrombinemia Treatment Market Size by Type
7.2.1 Europe Hypoprothrombinemia Treatment Market Size by Type (2017-2022)
7.2.2 Europe Hypoprothrombinemia Treatment Market Size by Type (2023-2028)
7.2.3 Europe Hypoprothrombinemia Treatment Market Share by Type (2017-2028)
7.3 Europe Hypoprothrombinemia Treatment Market Size by Application
7.3.1 Europe Hypoprothrombinemia Treatment Market Size by Application (2017-2022)
7.3.2 Europe Hypoprothrombinemia Treatment Market Size by Application (2023-2028)
7.3.3 Europe Hypoprothrombinemia Treatment Market Share by Application (2017-2028)
7.4 Europe Hypoprothrombinemia Treatment Market Size by Country
7.4.1 Europe Hypoprothrombinemia Treatment Market Size by Country (2017-2022)
7.4.2 Europe Hypoprothrombinemia Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hypoprothrombinemia Treatment Market Size (2017-2028)
8.2 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Type
8.2.1 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Hypoprothrombinemia Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Application
8.3.1 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Hypoprothrombinemia Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Region
8.4.1 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Hypoprothrombinemia Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hypoprothrombinemia Treatment Market Size (2017-2028)
9.2 Latin America Hypoprothrombinemia Treatment Market Size by Type
9.2.1 Latin America Hypoprothrombinemia Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Hypoprothrombinemia Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Hypoprothrombinemia Treatment Market Share by Type (2017-2028)
9.3 Latin America Hypoprothrombinemia Treatment Market Size by Application
9.3.1 Latin America Hypoprothrombinemia Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Hypoprothrombinemia Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Hypoprothrombinemia Treatment Market Share by Application (2017-2028)
9.4 Latin America Hypoprothrombinemia Treatment Market Size by Country
9.4.1 Latin America Hypoprothrombinemia Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Hypoprothrombinemia Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hypoprothrombinemia Treatment Market Size (2017-2028)
10.2 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Type
10.2.1 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Hypoprothrombinemia Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Application
10.3.1 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Hypoprothrombinemia Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Country
10.4.1 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Hypoprothrombinemia Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Hypoprothrombinemia Treatment Introduction
11.1.4 Roche Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Abbott
11.2.1 Abbott Company Details
11.2.2 Abbott Business Overview
11.2.3 Abbott Hypoprothrombinemia Treatment Introduction
11.2.4 Abbott Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.2.5 Abbott Recent Developments
11.3 Takeda Pharmaceutical Company
11.3.1 Takeda Pharmaceutical Company Company Details
11.3.2 Takeda Pharmaceutical Company Business Overview
11.3.3 Takeda Pharmaceutical Company Hypoprothrombinemia Treatment Introduction
11.3.4 Takeda Pharmaceutical Company Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.3.5 Takeda Pharmaceutical Company Recent Developments
11.4 CSL Limited
11.4.1 CSL Limited Company Details
11.4.2 CSL Limited Business Overview
11.4.3 CSL Limited Hypoprothrombinemia Treatment Introduction
11.4.4 CSL Limited Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.4.5 CSL Limited Recent Developments
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Hypoprothrombinemia Treatment Introduction
11.5.4 Bayer Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.5.5 Bayer Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Hypoprothrombinemia Treatment Introduction
11.6.4 Pfizer Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.6.5 Pfizer Recent Developments
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Hypoprothrombinemia Treatment Introduction
11.7.4 Novo Nordisk Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.7.5 Novo Nordisk Recent Developments
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Hypoprothrombinemia Treatment Introduction
11.8.4 Grifols Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.8.5 Grifols Recent Developments
11.9 Biogen
11.9.1 Biogen Company Details
11.9.2 Biogen Business Overview
11.9.3 Biogen Hypoprothrombinemia Treatment Introduction
11.9.4 Biogen Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.9.5 Biogen Recent Developments
11.10 BioMarin
11.10.1 BioMarin Company Details
11.10.2 BioMarin Business Overview
11.10.3 BioMarin Hypoprothrombinemia Treatment Introduction
11.10.4 BioMarin Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.10.5 BioMarin Recent Developments
11.11 BioSyent
11.11.1 BioSyent Company Details
11.11.2 BioSyent Business Overview
11.11.3 BioSyent Hypoprothrombinemia Treatment Introduction
11.11.4 BioSyent Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.11.5 BioSyent Recent Developments
11.12 Glenmark Pharmaceuticals
11.12.1 Glenmark Pharmaceuticals Company Details
11.12.2 Glenmark Pharmaceuticals Business Overview
11.12.3 Glenmark Pharmaceuticals Hypoprothrombinemia Treatment Introduction
11.12.4 Glenmark Pharmaceuticals Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.12.5 Glenmark Pharmaceuticals Recent Developments
11.13 Amarna Therapeutics
11.13.1 Amarna Therapeutics Company Details
11.13.2 Amarna Therapeutics Business Overview
11.13.3 Amarna Therapeutics Hypoprothrombinemia Treatment Introduction
11.13.4 Amarna Therapeutics Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.13.5 Amarna Therapeutics Recent Developments
11.14 Alnylam Pharmaceuticals
11.14.1 Alnylam Pharmaceuticals Company Details
11.14.2 Alnylam Pharmaceuticals Business Overview
11.14.3 Alnylam Pharmaceuticals Hypoprothrombinemia Treatment Introduction
11.14.4 Alnylam Pharmaceuticals Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.14.5 Alnylam Pharmaceuticals Recent Developments
11.15 Teva Pharmaceutical Industries
11.15.1 Teva Pharmaceutical Industries Company Details
11.15.2 Teva Pharmaceutical Industries Business Overview
11.15.3 Teva Pharmaceutical Industries Hypoprothrombinemia Treatment Introduction
11.15.4 Teva Pharmaceutical Industries Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.15.5 Teva Pharmaceutical Industries Recent Developments
11.16 Mylan
11.16.1 Mylan Company Details
11.16.2 Mylan Business Overview
11.16.3 Mylan Hypoprothrombinemia Treatment Introduction
11.16.4 Mylan Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.16.5 Mylan Recent Developments
11.17 Integra LifeSciences
11.17.1 Integra LifeSciences Company Details
11.17.2 Integra LifeSciences Business Overview
11.17.3 Integra LifeSciences Hypoprothrombinemia Treatment Introduction
11.17.4 Integra LifeSciences Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.17.5 Integra LifeSciences Recent Developments
11.18 Enzo Biochem
11.18.1 Enzo Biochem Company Details
11.18.2 Enzo Biochem Business Overview
11.18.3 Enzo Biochem Hypoprothrombinemia Treatment Introduction
11.18.4 Enzo Biochem Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.18.5 Enzo Biochem Recent Developments
11.19 Emcure
11.19.1 Emcure Company Details
11.19.2 Emcure Business Overview
11.19.3 Emcure Hypoprothrombinemia Treatment Introduction
11.19.4 Emcure Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.19.5 Emcure Recent Developments
11.20 Amgen
11.20.1 Amgen Company Details
11.20.2 Amgen Business Overview
11.20.3 Amgen Hypoprothrombinemia Treatment Introduction
11.20.4 Amgen Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.20.5 Amgen Recent Developments
11.21 Emergent
11.21.1 Emergent Company Details
11.21.2 Emergent Business Overview
11.21.3 Emergent Hypoprothrombinemia Treatment Introduction
11.21.4 Emergent Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.21.5 Emergent Recent Developments
11.22 Baxter
11.22.1 Baxter Company Details
11.22.2 Baxter Business Overview
11.22.3 Baxter Hypoprothrombinemia Treatment Introduction
11.22.4 Baxter Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.22.5 Baxter Recent Developments
11.23 Medtronic
11.23.1 Medtronic Company Details
11.23.2 Medtronic Business Overview
11.23.3 Medtronic Hypoprothrombinemia Treatment Introduction
11.23.4 Medtronic Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.23.5 Medtronic Recent Developments
11.24 Dr. Reddy’s Laboratories
11.24.1 Dr. Reddy’s Laboratories Company Details
11.24.2 Dr. Reddy’s Laboratories Business Overview
11.24.3 Dr. Reddy’s Laboratories Hypoprothrombinemia Treatment Introduction
11.24.4 Dr. Reddy’s Laboratories Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.24.5 Dr. Reddy’s Laboratories Recent Developments
11.25 Amneal Pharmaceuticals
11.25.1 Amneal Pharmaceuticals Company Details
11.25.2 Amneal Pharmaceuticals Business Overview
11.25.3 Amneal Pharmaceuticals Hypoprothrombinemia Treatment Introduction
11.25.4 Amneal Pharmaceuticals Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.25.5 Amneal Pharmaceuticals Recent Developments
11.26 Octapharma
11.26.1 Octapharma Company Details
11.26.2 Octapharma Business Overview
11.26.3 Octapharma Hypoprothrombinemia Treatment Introduction
11.26.4 Octapharma Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.26.5 Octapharma Recent Developments
11.27 Epitomepharm
11.27.1 Epitomepharm Company Details
11.27.2 Epitomepharm Business Overview
11.27.3 Epitomepharm Hypoprothrombinemia Treatment Introduction
11.27.4 Epitomepharm Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.27.5 Epitomepharm Recent Developments
11.28 Viramal
11.28.1 Viramal Company Details
11.28.2 Viramal Business Overview
11.28.3 Viramal Hypoprothrombinemia Treatment Introduction
11.28.4 Viramal Revenue in Hypoprothrombinemia Treatment Business (2017-2022)
11.28.5 Viramal Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Hypoprothrombinemia Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Type I Deficiency Treatment
Table 3. Key Players of Type II Deficiency Treatment
Table 4. Global Hypoprothrombinemia Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Hypoprothrombinemia Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Hypoprothrombinemia Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Hypoprothrombinemia Treatment Market Share by Region (2017-2022)
Table 8. Global Hypoprothrombinemia Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Hypoprothrombinemia Treatment Market Share by Region (2023-2028)
Table 10. Hypoprothrombinemia Treatment Market Trends
Table 11. Hypoprothrombinemia Treatment Market Drivers
Table 12. Hypoprothrombinemia Treatment Market Challenges
Table 13. Hypoprothrombinemia Treatment Market Restraints
Table 14. Global Hypoprothrombinemia Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Hypoprothrombinemia Treatment Revenue Share by Players (2017-2022)
Table 16. Global Top Hypoprothrombinemia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypoprothrombinemia Treatment as of 2021)
Table 17. Ranking of Global Top Hypoprothrombinemia Treatment Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Hypoprothrombinemia Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Hypoprothrombinemia Treatment Product Solution and Service
Table 21. Date of Enter into Hypoprothrombinemia Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Hypoprothrombinemia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Hypoprothrombinemia Treatment Revenue Market Share by Type (2017-2022)
Table 25. Global Hypoprothrombinemia Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Hypoprothrombinemia Treatment Revenue Market Share by Type (2023-2028)
Table 27. Global Hypoprothrombinemia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Hypoprothrombinemia Treatment Revenue Share by Application (2017-2022)
Table 29. Global Hypoprothrombinemia Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Hypoprothrombinemia Treatment Revenue Share by Application (2023-2028)
Table 31. North America Hypoprothrombinemia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Hypoprothrombinemia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Hypoprothrombinemia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Hypoprothrombinemia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Hypoprothrombinemia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Hypoprothrombinemia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Hypoprothrombinemia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Hypoprothrombinemia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Hypoprothrombinemia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Hypoprothrombinemia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Hypoprothrombinemia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Hypoprothrombinemia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Hypoprothrombinemia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Hypoprothrombinemia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Hypoprothrombinemia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Hypoprothrombinemia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Hypoprothrombinemia Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Hypoprothrombinemia Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Hypoprothrombinemia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Hypoprothrombinemia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Hypoprothrombinemia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Hypoprothrombinemia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Hypoprothrombinemia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Hypoprothrombinemia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Hypoprothrombinemia Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Hypoprothrombinemia Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Hypoprothrombinemia Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Hypoprothrombinemia Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Hypoprothrombinemia Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Hypoprothrombinemia Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Hypoprothrombinemia Treatment Product
Table 64. Roche Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 65. Roche Recent Developments
Table 66. Abbott Company Details
Table 67. Abbott Business Overview
Table 68. Abbott Hypoprothrombinemia Treatment Product
Table 69. Abbott Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 70. Abbott Recent Developments
Table 71. Takeda Pharmaceutical Company Company Details
Table 72. Takeda Pharmaceutical Company Business Overview
Table 73. Takeda Pharmaceutical Company Hypoprothrombinemia Treatment Product
Table 74. Takeda Pharmaceutical Company Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 75. Takeda Pharmaceutical Company Recent Developments
Table 76. CSL Limited Company Details
Table 77. CSL Limited Business Overview
Table 78. CSL Limited Hypoprothrombinemia Treatment Product
Table 79. CSL Limited Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 80. CSL Limited Recent Developments
Table 81. Bayer Company Details
Table 82. Bayer Business Overview
Table 83. Bayer Hypoprothrombinemia Treatment Product
Table 84. Bayer Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 85. Bayer Recent Developments
Table 86. Pfizer Company Details
Table 87. Pfizer Business Overview
Table 88. Pfizer Hypoprothrombinemia Treatment Product
Table 89. Pfizer Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 90. Pfizer Recent Developments
Table 91. Novo Nordisk Company Details
Table 92. Novo Nordisk Business Overview
Table 93. Novo Nordisk Hypoprothrombinemia Treatment Product
Table 94. Novo Nordisk Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 95. Novo Nordisk Recent Developments
Table 96. Grifols Company Details
Table 97. Grifols Business Overview
Table 98. Grifols Hypoprothrombinemia Treatment Product
Table 99. Grifols Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 100. Grifols Recent Developments
Table 101. Biogen Company Details
Table 102. Biogen Business Overview
Table 103. Biogen Hypoprothrombinemia Treatment Product
Table 104. Biogen Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 105. Biogen Recent Developments
Table 106. BioMarin Company Details
Table 107. BioMarin Business Overview
Table 108. BioMarin Hypoprothrombinemia Treatment Product
Table 109. BioMarin Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 110. BioMarin Recent Developments
Table 111. BioSyent Company Details
Table 112. BioSyent Business Overview
Table 113. BioSyent Hypoprothrombinemia Treatment Product
Table 114. BioSyent Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 115. BioSyent Recent Developments
Table 116. Glenmark Pharmaceuticals Company Details
Table 117. Glenmark Pharmaceuticals Business Overview
Table 118. Glenmark Pharmaceuticals Hypoprothrombinemia Treatment Product
Table 119. Glenmark Pharmaceuticals Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 120. Glenmark Pharmaceuticals Recent Developments
Table 121. Amarna Therapeutics Company Details
Table 122. Amarna Therapeutics Business Overview
Table 123. Amarna Therapeutics Hypoprothrombinemia Treatment Product
Table 124. Amarna Therapeutics Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 125. Amarna Therapeutics Recent Developments
Table 126. Alnylam Pharmaceuticals Company Details
Table 127. Alnylam Pharmaceuticals Business Overview
Table 128. Alnylam Pharmaceuticals Hypoprothrombinemia Treatment Product
Table 129. Alnylam Pharmaceuticals Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 130. Alnylam Pharmaceuticals Recent Developments
Table 131. Teva Pharmaceutical Industries Company Details
Table 132. Teva Pharmaceutical Industries Business Overview
Table 133. Teva Pharmaceutical Industries Hypoprothrombinemia Treatment Product
Table 134. Teva Pharmaceutical Industries Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 135. Teva Pharmaceutical Industries Recent Developments
Table 136. Mylan Company Details
Table 137. Mylan Business Overview
Table 138. Mylan Hypoprothrombinemia Treatment Product
Table 139. Mylan Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 140. Mylan Recent Developments
Table 141. Integra LifeSciences Company Details
Table 142. Integra LifeSciences Business Overview
Table 143. Integra LifeSciences Hypoprothrombinemia Treatment Product
Table 144. Integra LifeSciences Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 145. Integra LifeSciences Recent Developments
Table 146. Enzo Biochem Company Details
Table 147. Enzo Biochem Business Overview
Table 148. Enzo Biochem Hypoprothrombinemia Treatment Product
Table 149. Enzo Biochem Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 150. Enzo Biochem Recent Developments
Table 151. Emcure Company Details
Table 152. Emcure Business Overview
Table 153. Emcure Hypoprothrombinemia Treatment Product
Table 154. Emcure Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 155. Emcure Recent Developments
Table 156. Amgen Company Details
Table 157. Amgen Business Overview
Table 158. Amgen Hypoprothrombinemia Treatment Product
Table 159. Amgen Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 160. Amgen Recent Developments
Table 161. Emergent Company Details
Table 162. Emergent Business Overview
Table 163. Emergent Hypoprothrombinemia Treatment Product
Table 164. Emergent Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 165. Emergent Recent Developments
Table 166. Baxter Company Details
Table 167. Baxter Business Overview
Table 168. Baxter Hypoprothrombinemia Treatment Product
Table 169. Baxter Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 170. Baxter Recent Developments
Table 171. Medtronic Company Details
Table 172. Medtronic Business Overview
Table 173. Medtronic Hypoprothrombinemia Treatment Product
Table 174. Medtronic Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 175. Medtronic Recent Developments
Table 176. Dr. Reddy’s Laboratories Company Details
Table 177. Dr. Reddy’s Laboratories Business Overview
Table 178. Dr. Reddy’s Laboratories Hypoprothrombinemia Treatment Product
Table 179. Dr. Reddy’s Laboratories Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 180. Dr. Reddy’s Laboratories Recent Developments
Table 181. Amneal Pharmaceuticals Company Details
Table 182. Amneal Pharmaceuticals Business Overview
Table 183. Amneal Pharmaceuticals Hypoprothrombinemia Treatment Product
Table 184. Amneal Pharmaceuticals Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 185. Amneal Pharmaceuticals Recent Developments
Table 186. Octapharma Company Details
Table 187. Octapharma Business Overview
Table 188. Octapharma Hypoprothrombinemia Treatment Product
Table 189. Octapharma Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 190. Octapharma Recent Developments
Table 191. Epitomepharm Company Details
Table 192. Epitomepharm Business Overview
Table 193. Epitomepharm Hypoprothrombinemia Treatment Product
Table 194. Epitomepharm Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 195. Epitomepharm Recent Developments
Table 196. Viramal Company Details
Table 197. Viramal Business Overview
Table 198. Viramal Hypoprothrombinemia Treatment Product
Table 199. Viramal Revenue in Hypoprothrombinemia Treatment Business (2017-2022) & (US$ Million)
Table 200. Viramal Recent Developments
Table 201. Research Programs/Design for This Report
Table 202. Key Data Information from Secondary Sources
Table 203. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hypoprothrombinemia Treatment Market Share by Type: 2021 VS 2028
Figure 2. Type I Deficiency Treatment Features
Figure 3. Type II Deficiency Treatment Features
Figure 4. Global Hypoprothrombinemia Treatment Market Share by Application: 2021 VS 2028
Figure 5. Hospital Case Studies
Figure 6. Home Care Case Studies
Figure 7. Specialist Clinic Case Studies
Figure 8. Hypoprothrombinemia Treatment Report Years Considered
Figure 9. Global Hypoprothrombinemia Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Hypoprothrombinemia Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Hypoprothrombinemia Treatment Market Share by Region: 2021 VS 2028
Figure 12. Global Hypoprothrombinemia Treatment Market Share by Players in 2021
Figure 13. Global Top Hypoprothrombinemia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypoprothrombinemia Treatment as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Hypoprothrombinemia Treatment Revenue in 2021
Figure 15. North America Hypoprothrombinemia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America Hypoprothrombinemia Treatment Market Size Market Share by Type (2017-2028)
Figure 17. North America Hypoprothrombinemia Treatment Market Size Market Share by Application (2017-2028)
Figure 18. North America Hypoprothrombinemia Treatment Market Size Share by Country (2017-2028)
Figure 19. United States Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Hypoprothrombinemia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe Hypoprothrombinemia Treatment Market Size Market Share by Type (2017-2028)
Figure 23. Europe Hypoprothrombinemia Treatment Market Size Market Share by Application (2017-2028)
Figure 24. Europe Hypoprothrombinemia Treatment Market Size Share by Country (2017-2028)
Figure 25. Germany Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Hypoprothrombinemia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Hypoprothrombinemia Treatment Market Size Market Share by Type (2017-2028)
Figure 33. Asia Pacific Hypoprothrombinemia Treatment Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific Hypoprothrombinemia Treatment Market Size Share by Region (2017-2028)
Figure 35. China Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America Hypoprothrombinemia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America Hypoprothrombinemia Treatment Market Size Market Share by Type (2017-2028)
Figure 43. Latin America Hypoprothrombinemia Treatment Market Size Market Share by Application (2017-2028)
Figure 44. Latin America Hypoprothrombinemia Treatment Market Size Share by Country (2017-2028)
Figure 45. Mexico Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Hypoprothrombinemia Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa Hypoprothrombinemia Treatment Market Size Market Share by Type (2017-2028)
Figure 49. Middle East and Africa Hypoprothrombinemia Treatment Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa Hypoprothrombinemia Treatment Market Size Share by Country (2017-2028)
Figure 51. Turkey Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE Hypoprothrombinemia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Roche Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 55. Abbott Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 56. Takeda Pharmaceutical Company Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 57. CSL Limited Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 58. Bayer Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 59. Pfizer Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 60. Novo Nordisk Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 61. Grifols Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 62. Biogen Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 63. BioMarin Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 64. BioSyent Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 65. Glenmark Pharmaceuticals Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 66. Amarna Therapeutics Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 67. Alnylam Pharmaceuticals Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 68. Teva Pharmaceutical Industries Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 69. Mylan Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 70. Integra LifeSciences Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 71. Enzo Biochem Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 72. Emcure Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 73. Amgen Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 74. Emergent Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 75. Baxter Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 76. Medtronic Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 77. Dr. Reddy’s Laboratories Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 78. Amneal Pharmaceuticals Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 79. Octapharma Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 80. Epitomepharm Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 81. Viramal Revenue Growth Rate in Hypoprothrombinemia Treatment Business (2017-2022)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed

---